Skip to main content
SpringerLink
Log in

Plasminogen activator inhibitor-1 polymorphisms (−844 G>A and HindIII C>G) in systemic lupus erythematosus: association with clinical variables

  • Original Article
  • Published:
Clinical and Experimental Medicine Aims and scope Submit manuscript

Abstract

Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by the presence of autoantibodies against nuclear autoantigens as well as cytoplasmic and circulating proteins. Recent studies have demonstrated mechanisms responsible for modulation of the immune response by the plasminogen activator inhibitor-1 (PAI-1). Furthermore, the endogenous PAI-1 has shown to promote a Th2 immune response. We assessed the −844 G>A and HindIII C>G PAI-1 polymorphisms in SLE. In a case–control study of 71 SLE patients classified according to ACR criteria and 71 healthy subjects (HS). The A allele of −844 PAI-1 polymorphism showed a significant difference in SLE patients (41%) when compared with HS (27%) [P = 0.01; OR = 1.8, 95%, CI = 1.1–3.0]. In addition, the −844 G>A PAI-1 polymorphism was associated with increased risk for SLE in a dominant genetic model (G/G vs. G/A + A/A; OR = 2.3, 95% CI = 1.14–4.44). Also, anti-RNP positive antibodies in SLE were associated with G/G −844 PAI-1 genotype. The HindIII polymorphism did not show any differences. The haplotype analysis showed that the AC haplotype confers susceptibility to SLE (OR = 3.1, 95% CI, 1.45–6.52; P = 0.003). The AC haplotype of the −844 and HindIII PAI-1 polymorphism might be an additional susceptibility factor to SLE in Mexicans.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Petri M (2006) Systemic lupus erythematosus: 2006 update. J Clin Rheumatol 12:37–40

    Article  PubMed  Google Scholar 

  2. Edberg JC, Wu J, Langefeld CD, Brown EE, Marion MC, McGwin G Jr, Petri M, Ramsey-Goldman R, Reveille JD, Frank SG, Kaufman KM, Harley JB, Alarcón GS, Kimberly RP (2008) Genetic variation in the CRP promoter: association with systemic lupus erythematosus. Hum Mol Genet 17:1147–1155

    Article  CAS  PubMed  Google Scholar 

  3. Fernández M, Alarcón G, Calvo-Alén J, Andrade R, McGwin G Jr, Vilá LM, Reveille JD, LUMINA Study Group (2007) A multiethnic, multicenter cohort of patients with systemic lupus erythematosus (SLE) as a model for the study of ethnic disparities in SLE. Arthritis Rheum 57:576–584

    Article  PubMed  Google Scholar 

  4. Palafox-Sánchez CA, Vázquez-Del Mercado M, Orozco-Barocio G, Torre IG, Torres-Carrillo N, Torres-Carrillo NM, Illades-Aguiar B, Muñoz Valle JF (2009) A functional Ser413/Ser413 PAI-2 polymorphism is associated with susceptibility and damage index score in systemic lupus erythematosus. Clin Appl Thromb Hemost 15:233–238

    Article  PubMed  Google Scholar 

  5. Wang AY, Ponn P, Lai FM, Yu L, Choi PC, Lui SF, Li PK (2001) Plasminogen activator inhibitor-1 gene polymorphism 4G/4G genotype and lupus nephritis in Chinese patients. Kidney Int 59:1520–1528

    Article  CAS  PubMed  Google Scholar 

  6. Tassies D, Espinosa G, Muñoz-Rodriguez FJ, Freire C, Cervera R, Monteagudo J, Maragall S, Escolar G, Ingelmo M, Ordinas A, Font J, Reverter JC (2000) The 4G/5G polymorphism of the type 1 plasminogen activator inhibitor gene and thrombosis in patients with antiphospholipid syndrome. Arthritis Rheum 43:2349–2358

    Article  CAS  PubMed  Google Scholar 

  7. Huber K (2001) Plasminogen activator inhibitor type-1 (Part One): basic mechanisms, regulation, and role for thromboembolic disease. J Thromb Thrombolysis 11:183–193

    Article  CAS  PubMed  Google Scholar 

  8. Gils A, Declerck PJ (2004) Plasminogen activator inhibitor-1. Curr Med Chem 11:2323–2334

    CAS  PubMed  Google Scholar 

  9. Binder BR, Christ G, Gruber F, Grubic N, Hufnagl P, Krebs M, Mihaly J, Prager GW (2002) Plasminogen activator inhibitor 1: physiological and pathophysiological roles. News Physiol Sci 17:56–61

    CAS  PubMed  Google Scholar 

  10. Morange PE, Henry M, Tregouët B, Granel B, Aillaud MF, Alessi MC, Juhan-Vague I (2000) The A -844G polymorphism in the PAI-1 gene is associated with a higher risk of venous thrombosis in Factor V Leiden carriers. Arterioscler Thromb Vasc Biol 20:1387–1391

    CAS  PubMed  Google Scholar 

  11. Adamski MG, Turaj W, Slowik A, Wloch-Kopec D, Wolkow P, Szczudlik A (2009) A-G-4G haplotype of PAI-1 gene polymorphisms -844 G/A, HindIII G/C, and -675 4G/5G is associated with increased risk of ischemic stroke caused by small vessel disease. Acta Neurol Scand 120:94–100

    Article  CAS  PubMed  Google Scholar 

  12. Sejima T, Madoiwa S, Mimuro J, Sugo T, Okada K, Ueshima S, Matsuo O, Ishida T, Ichimura K, Sakata Y (2005) Protection of plasminogen activator inhibitor-1-deficient mice from nasal allergy. J Immunol 174:8135–8143

    CAS  PubMed  Google Scholar 

  13. Renckens R, Pater JM, van der Poll T (2006) Plasminogen activator inhibitor type-1-deficient mice have enhanced IFN-g response to lipopolysaccharide and staphylococcal enterotoxin B. J Immunol 177:8171–8176

    CAS  PubMed  Google Scholar 

  14. Hirankarn N, Tangwattanachuleeporn M, Wongpiyabovorn J, Wongchinsri J, Avihingsanon Y (2009) Association of IL-18 gene polymorphism (−137C) with arthritis manifestations in SLE: combined effect with IFN gamma gene polymorphism (+874A). Clin Rheumatol 28:219–223

    Article  PubMed  Google Scholar 

  15. Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:1215

    Article  CAS  PubMed  Google Scholar 

  16. Zaykin D, Zhivotovsky L, Weir BS (1995) Exact test for association between alleles at arbitrary numbers of loci. Genetic 96:169–178. [GDA program]. Version 1.1

    Google Scholar 

  17. Excoffier L, Staltkin M (1995) Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol Biol Evol 12:921–927

    CAS  PubMed  Google Scholar 

  18. Criswell LA (2008) The genetic contribution to systemic lupus erythematosus. Bull NYU Hosp Jt Dis 66:176–183

    PubMed  Google Scholar 

  19. Pullmann R Jr, Bonilla E, Phillips PE, Middleton FA, Perl A (2008) Haplotypes of the HRES-1 endogenous retrovirus are associated with development and disease manifestations of systemic lupus erythematosus. Arthritis Rheum 58:532–540

    Article  CAS  PubMed  Google Scholar 

  20. Christiansen FT, Zhang WJ, Griffiths M, Mallal SA, Dawkins RL (1991) Major histocompatibility complex (MHC) complement deficiency, ancestral haplotypes and systemic lupus erythematosus (SLE): C4 deficiency explains some but not all of the influence of the MHC. J Rheumatol 18:1350–1358

    CAS  PubMed  Google Scholar 

  21. Duits AJ, Bootsma H, Derksen RH, Spronk PE, Kater L, Kallenberg CG, Capel PJ, Westerdaal NA, Spierenburg GT, Gmelig-Meyling FH et al (1995) Skewed distribution of IgG Fc receptor IIa (CD32) polymorphism is associated with renal disease in systemic lupus erythematosus patients. Arthritis Rheum 38:1832–1836

    Article  CAS  PubMed  Google Scholar 

  22. Sullivan KE, Jawad AF, Piliero LM, Kim N, Luan X, Goldman D, Petri M (2003) Analysis of polymorphisms affecting immune complex handling in systemic lupus erythematosus. Rheumatology (Oxford) 42:446–452

    Article  CAS  Google Scholar 

  23. Graham RR, Kozyrev SV, Baechler EC, Reddy MV, Plenge RM, Bauer JW, Ortmann WA, Koeuth T, González Escribano MF, Argentine and Spanish Collaborative Groups, Pons-Estel B, Petri M, Daly M, Gregersen PK, Martín J, Altshuler D, Behrens TW, Alarcón-Riquelme ME (2006) A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet 38:550–555

    Article  CAS  PubMed  Google Scholar 

  24. Remmers EF, Plenge RM, Lee AT, Graham RR, Hom G, Behrens TW, de Bakker PI, Le JM, Lee HS, Batliwalla F, Li W, Masters SL, Booty MG, Carulli JP, Padyukov L, Alfredsson L, Klareskog L, Chen WV, Amos CI, Criswell LA, Seldin MF, Kastner DL, Gregersen PK (2007) STAT4 and the risk of rheumatoid artritis and systemic lupus erythematosus. N Engl J Med 357:977–986

    Article  CAS  PubMed  Google Scholar 

  25. Hom G, Graham RR, Modrek B, Taylor KE, Ortmann W, Garnier S, Lee AT, Chung SA, Ferreira RC, Pant PV, Ballinger DG, Kosoy R, Demirci FY, Kamboh MI, Kao AH, Tian C, Gunnarsson I, Bengtsson AA, Rantapää-Dahlqvist S, Petri M, Manzi S, Seldin MF, Rönnblom L, Syvänen AC, Criswell LA, Gregersen PK, Behrens TW (2008) Association of systemic lupus erythematosus with C8orf13–BLK and ITGAM–ITGAX. N Engl J Med 358:900–909

    Article  CAS  PubMed  Google Scholar 

  26. Gong R, Liu Z, Li L (2007) Epistatic effect of plasminogen activator inhibitor 1 and beta-fibrinogen genes on risk of glomerular microthrombosis in lupus nephritis: interaction with environmental/clinical factors. Arthritis Rheum 56:1608–1617

    Article  CAS  PubMed  Google Scholar 

  27. Akey J, Jin L, Xiong M (2001) Haplotypes vs single marker linkage disequilibrium tests: what do we gain? Eur J Hum Genet 9:291–300

    Article  CAS  PubMed  Google Scholar 

  28. Henry M, Chomiki N, Scarabin PY, Alessi MC, Peiretti F, Arveiler D, Ferrières J, Evans A, Amouyel P, Poirier O, Cambien F, Juhan-Vague I (1997) Five frequent polymorphisms of the PAI-1 gene: lack of association between genotypes, PAI activity, and triglyceride levels in a healthy population. Arterioscler Thromb Vasc Biol 17:851–858

    CAS  PubMed  Google Scholar 

  29. Dawson S, Hamsten A, Wiman B, Henney A, Humphries S (1991) Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb 11:183–190

    CAS  PubMed  Google Scholar 

  30. Torres-Carrillo N, Magdalena Torres-Carrillo N, Vázquez-Del Mercado M, Rangel-Villalobos H, Parra-Rojas I, Sánchez-Enríquez S, Muñoz-Valle JF (2008) Distribution of -844 G/A and HindIII C/G PAI-1 polymorphisms and plasma PAI-1 levels in Mexican subjects: comparison of frequencies between populations. Clin Appl Thromb Hemost 14:220–226

    Article  CAS  PubMed  Google Scholar 

  31. Su S, Chen S, Zhao J, Huang J, Wang X, Chen R, Gu D (2006) Plasminogen activator inhibitor-1 gene: selection of tagging single nucleotide polymorphisms and association with coronary heart disease. Arterioscler Thromb Vasc Biol 26:948–954

    Article  CAS  PubMed  Google Scholar 

  32. Alba P, Bento L, Cuadrado MJ, Karim Y, Tungekar MF, Abbs I, Khamashta MA, D’Cruz D, Hughes GR (2003) Anti-dsDNA, anti-Sm antibodies, and the lupus anticoagulant: significant factors associated with lupus nephritis. Ann Rheum Dis 62:556–560

    Article  CAS  PubMed  Google Scholar 

  33. Chen JY, Wang CM, Ma CC, Luo SF, Edberg JC, Kimberly RP, Wu J (2006) Association of a transmembrane polymorphism of Fcgamma receptor IIb (FCGR2B) with systemic lupus erythematosus in Taiwanese patients. Arthritis Rheum 54:3908–3917

    Article  CAS  PubMed  Google Scholar 

  34. Fritzler MJ, Wiik A, Tan EM, Smolen JS, McDougal JS, Chan EK, Gordon TP, Hardin JA, Kalden JR, Lahita RG, Maini RN, Reeves WH, Rothfield NF, Takasaki Y, Wilson M, Byrd MG, Slivka L, Koziol JA (2003) A critical evaluation of enzyme immunoassay kits for detection of antinuclear autoantibodies of defined specificities. J Rheumatol 30:2374–2381

    CAS  PubMed  Google Scholar 

  35. Torres-Carrillo N, Torres-Carrillo NM, Martínez-Bonilla GE, Vázquez-Del Mercado M, Palafox-Sánchez CA, Oregón-Romero E, Bernard-Medina AG, Rangel-Villalobos H, Muñoz-Valle JF (2009) Plasminogen activator inhibitor-1 C/G polymorphism in relation to plasma levels in rheumatoid arthritis. Clin Exp Med 9:223–228

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

To all the volunteers who participated in this study.

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, Departamento de Biología Molecular y Genómica, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Insurgentes 244-1, Colonia Lomas de Atemajac, 45178, Zapopan, Jalisco, México

    Jorge Ramón Padilla-Gutiérrez, Claudia Azucena Palafox-Sánchez, Yeminia Valle, Edith Oregón-Romero, Mónica Vázquez-Del Mercado, Mara Anaís Llamas-Covarrubias & José Francisco Muñoz-Valle

  2. Posdoctoral Fellow in Biomedical Sciences (Immunology). Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, México

    Jorge Ramón Padilla-Gutiérrez & Yeminia Valle

  3. Departamento de Inmunología y Reumatología del Hospital General de Occidente, Secretaría de Salud Jalisco, Av. Zoquipan 1050, 45100, Zapopan, Jalisco, México

    Gerardo Orozco-Barocio

  4. Instituto de Investigación en Genética Molecular, Centro Universitario de la Ciénega, Universidad de Guadalajara, Ocotlán, Jalisco, México

    Héctor Rangel-Villalobos

Authors
  1. Jorge Ramón Padilla-Gutiérrez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Claudia Azucena Palafox-Sánchez
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yeminia Valle
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gerardo Orozco-Barocio
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Edith Oregón-Romero
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mónica Vázquez-Del Mercado
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Héctor Rangel-Villalobos
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Mara Anaís Llamas-Covarrubias
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. José Francisco Muñoz-Valle
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to José Francisco Muñoz-Valle.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Padilla-Gutiérrez, J.R., Palafox-Sánchez, C.A., Valle, Y. et al. Plasminogen activator inhibitor-1 polymorphisms (−844 G>A and HindIII C>G) in systemic lupus erythematosus: association with clinical variables. Clin Exp Med 11, 11–17 (2011). https://doi.org/10.1007/s10238-010-0099-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10238-010-0099-0

Keywords

Search

Navigation